Proton Pump Inhibitors for Inhibition of Aortic Valve Calcification

USPTO published patent application US20260097026A1 covering the use of proton pump inhibitors including prazole compounds for inhibiting aortic valve calcification and treating related diseases such as aortic sclerosis and stenosis. The application was filed on October 3, 2023 (Application No. 19115899) and published on April 9, 2026 as an A1 publication (original application as filed).\n\nAffected parties in the pharmaceutical and medical device sectors should monitor this application for potential blocking patents in the cardiovascular treatment space. Competitors developing similar proton pump inhibitor formulations for cardiovascular applications may need to conduct Freedom to Operate analyses or consider licensing discussions upon patent grant. This publication does not create immediate compliance obligations but signals potential future IP barriers in aortic valve calcification treatment.